GADD45β inhibits RIPK3-mediated NF-κB activation by interfering with NEMO-RIPK1-RIPK3 interactions.

Area of Science:

• Immunology
• Cell Biology
• Molecular Biology

Background:

• Necroptosis, a regulated cell death pathway driven by RIPK3, is integral to immune responses and inflammation.
• RIPK3 signaling activates NF-κB, promoting cytokine production, but its regulation is poorly understood.
• Understanding RIPK3 regulation is crucial for modulating inflammatory diseases and the tumor microenvironment.

Purpose of the Study:

• To identify novel regulators of RIPK3-mediated NF-κB activation.
• To elucidate the mechanism by which GADD45β influences RIPK3 signaling.
• To explore the therapeutic potential of GADD45β in controlling necroptosis-induced inflammation.

Main Methods:

• Co-immunoprecipitation assays to detect protein-protein interactions.
• Western blotting to assess protein phosphorylation and signaling pathway activation.
• Cellular assays to measure cytokine production (CXCL8/IL-8) and cell death.

Main Results:

• Growth Arrest and DNA Damage-inducible β (GADD45β) was identified as a direct RIPK3 binding partner.
• GADD45β binding to RIPK3 is RHIM-independent and inhibits RIPK3-mediated NF-κB activation.
• Inducible GADD45β expression suppressed RIPK3-induced inflammation (CXCL8 production) without increasing apoptosis and enhanced cell survival.

Conclusions:

• GADD45β acts as a novel negative regulator of RIPK3-driven NF-κB signaling and necroptotic inflammation.
• GADD45β selectively dampens RIPK3-induced immune responses, offering a potential therapeutic avenue.
• Targeting GADD45β could provide a strategy for managing inflammatory conditions and modulating immunogenic cell death.